S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
MarketBeat Week in Review – 2/19 - 2/23
Taiwan giant chipmaker TSMC opens first plant in Japan as part of key global expansion
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
A collection of the insights Warren Buffett offered in his annual letter Saturday
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Macron booed by French farmers who blame him for not doing enough to support agriculture
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
MarketBeat Week in Review – 2/19 - 2/23
Taiwan giant chipmaker TSMC opens first plant in Japan as part of key global expansion
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
A collection of the insights Warren Buffett offered in his annual letter Saturday
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Macron booed by French farmers who blame him for not doing enough to support agriculture
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
MarketBeat Week in Review – 2/19 - 2/23
Taiwan giant chipmaker TSMC opens first plant in Japan as part of key global expansion
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
A collection of the insights Warren Buffett offered in his annual letter Saturday
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Macron booed by French farmers who blame him for not doing enough to support agriculture
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
MarketBeat Week in Review – 2/19 - 2/23
Taiwan giant chipmaker TSMC opens first plant in Japan as part of key global expansion
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
A collection of the insights Warren Buffett offered in his annual letter Saturday
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Macron booed by French farmers who blame him for not doing enough to support agriculture

VYNE Therapeutics (VYNE) Stock Forecast & Price Target

$2.26
+0.09 (+4.15%)
(As of 02/23/2024 ET)

VYNE Therapeutics Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Buy
Based on 1 Analyst Ratings

Analysts' Consensus Price Target

$7.38
226.33% Upside
High Forecast$9.00
Average Forecast$7.38
Low Forecast$5.75
TypeCurrent Forecast
2/24/23 to 2/24/24
1 Month Ago
1/25/23 to 1/25/24
3 Months Ago
11/26/22 to 11/26/23
1 Year Ago
2/24/22 to 2/24/23
Consensus Rating
Buy
Buy
Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
1 Buy rating(s)
1 Buy rating(s)
1 Buy rating(s)
2 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
1 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$7.38$7.38$7.38$27.00
Predicted Upside226.33% Upside89.10% Upside89.10% Upside457.62% Upside
Get VYNE Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for VYNE and its competitors with MarketBeat's FREE daily newsletter.


VYNE Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

VYNE Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

VYNE Therapeutics Stock vs. The Competition

TypeVYNE TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.68
2.48
Consensus RatingBuyModerate BuyHold
Predicted Upside226.33% Upside1,899.57% Upside7.54% Upside
News Sentiment RatingPositive News
Neutral News
Positive News

Recent Analyst Ratings and Stock Forecasts

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
10/30/2023HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$28.00 ➝ $5.75+105.36%
5/12/2023Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$5.00 ➝ $9.00+47.54%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 09:43 PM ET.












VYNE Price Target - Frequently Asked Questions

What is VYNE Therapeutics's consensus rating and price target?

According to the issued ratings of 1 analysts in the last year, the consensus rating for VYNE Therapeutics stock is Buy based on the current 1 buy rating for VYNE. The average twelve-month price prediction for VYNE Therapeutics is $7.38 with a high price target of $9.00 and a low price target of $5.75. Learn more on VYNE's analyst rating history.

Do Wall Street analysts like VYNE Therapeutics more than its competitors?

Analysts like VYNE Therapeutics more than other Medical companies. The consensus rating for VYNE Therapeutics is Buy while the average consensus rating for medical companies is Moderate Buy. Learn more on how VYNE compares to other companies.

Does VYNE Therapeutics's stock price have much upside?

According to analysts, VYNE Therapeutics's stock has a predicted upside of 89.10% based on their 12-month stock forecasts.


Stock Ratings Reports and Tools

This page (NASDAQ:VYNE) was last updated on 2/24/2024 by MarketBeat.com Staff